$3.86
0.26% yesterday
Nasdaq, Sep 16, 10:00 pm CET
ISIN
IL0011839383
Symbol
DRTS

Alpha Tau Medical Stock price

$3.86
+0.60 18.41% 1M
+1.20 45.12% 6M
+0.76 24.52% YTD
+1.57 68.56% 1Y
-2.23 36.62% 3Y
-6.24 61.78% 5Y
-6.24 61.78% 10Y
-6.24 61.78% 20Y
Nasdaq, Closing price Tue, Sep 16 2025
+0.01 0.26%
ISIN
IL0011839383
Symbol
DRTS

Key metrics

Basic
Market capitalization
$327.0m
Enterprise Value
$253.3m
Net debt
positive
Cash
$79.7m
Shares outstanding
70.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
72.7%
Return on Equity
-50.7%
ROCE
-36.5%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-36.5m | $-44.9m
EBIT
$-37.5m | $-40.4m
Net Income
$-35.2m | $-35.1m
Free Cash Flow
$-26.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-3.5% | -28.6%
EBIT
-3.2% | -12.1%
Net Income
-27.4% | -10.5%
Free Cash Flow
-0.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
0.1%
Employees
125
Rev per Employee
$0.0
Show more

Is Alpha Tau Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Alpha Tau Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Alpha Tau Medical forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Alpha Tau Medical forecast:

Buy
90%
Hold
10%

Financial data from Alpha Tau Medical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.63 9.63
9% 9%
-
- Research and Development Expense 28 28
2% 2%
-
-36 -36
3% 3%
-
- Depreciation and Amortization 1.08 1.08
4% 4%
-
EBIT (Operating Income) EBIT -38 -38
3% 3%
-
Net Profit -35 -35
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alpha Tau Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alpha Tau Medical Stock News

Neutral
GlobeNewsWire
15 days ago
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –
Neutral
GlobeNewsWire
21 days ago
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.
Neutral
GlobeNewsWire
about one month ago
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -
More Alpha Tau Medical News

Company Profile

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Uzi Sofer
Employees 125
Founded 2015
Website www.alphatau.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today